Clinical Trial Update: ATG Plus Low-dose PT-Cy for GVHD Prevention [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ATG plus low-dose post-transplant cyclophosphamide for graft-versus-host disease prevention in hematologic malignancies has been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• ATG (anti-thymocyte globulin)
• Cyclophosphamide (PT-Cy) (cyclophosphamide)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Hematologic Malignancy | Phase 3 | Status: TERMINATED